Innate Pharma S.A. (IPHA)

Innate Pharma Statistics

Total Valuation

Innate Pharma has a market cap or net worth of $162.24 million. The enterprise value is $103.60 million.

Market Cap	162.24M
Enterprise Value	103.60M

Important Dates

The last earnings date was Thursday, September 12, 2024, before market open.

Earnings Date	Sep 12, 2024
Ex-Dividend Date	n/a

Share Statistics

Innate Pharma has 80.95 million shares outstanding. The number of shares has increased by 1.01% in one year.

Current Share Class	n/a
Shares Outstanding	80.95M
Shares Change (YoY)	+1.01%
Shares Change (QoQ)	+0.35%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	31.56M

Valuation Ratios

PE Ratio	n/a
Forward PE	2.49
PS Ratio	n/a
Forward PS	n/a
PB Ratio	n/a
P/TBV Ratio	5.28
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	2.86
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.92, with a Debt / Equity ratio of 1.23.

Current Ratio	2.92
Quick Ratio	2.76
Debt / Equity	1.23
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-62.63

Financial Efficiency

Return on equity (ROE) is -78.59% and return on invested capital (ROIC) is -29.62%.

Return on Equity (ROE)	-78.59%
Return on Assets (ROA)	-13.76%
Return on Capital (ROIC)	-29.62%
Revenue Per Employee	$202,250
Profits Per Employee	-$203,830
Employee Count	179
Asset Turnover	0.19
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -23.79% in the last 52 weeks. The beta is 0.87, so Innate Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.87
52-Week Price Change	-23.79%
50-Day Moving Average	1.82
200-Day Moving Average	2.23
Relative Strength Index (RSI)	53.32
Average Volume (20 Days)	1,473,785

Short Selling Information

Short Interest	62,946
Short Previous Month	63,718
Short % of Shares Out	0.14%
Short % of Float	n/a
Short Ratio (days to cover)	5.63

Income Statement

In the last 12 months, Innate Pharma had revenue of $36.20 million and -$36.49 million in losses. Loss per share was -$0.45.

Revenue	36.20M
Gross Profit	-21.28M
Operating Income	-41.34M
Pretax Income	-8.28M
Net Income	-36.49M
EBITDA	-38.53M
EBIT	-41.34M
Loss Per Share	-$0.45

Balance Sheet

The company has $98.36 million in cash and $38.04 million in debt, giving a net cash position of $60.32 million or $0.75 per share.

Cash & Cash Equivalents	98.36M
Total Debt	38.04M
Net Cash	60.32M
Net Cash Per Share	$0.75
Equity (Book Value)	30.85M
Book Value Per Share	0.38
Working Capital	78.61M

Cash Flow

In the last 12 months, operating cash flow was -$19.35 million and capital expenditures -$348,227, giving a free cash flow of -$19.18 million.

Operating Cash Flow	-19.35M
Capital Expenditures	-348,227
Free Cash Flow	-19.18M
FCF Per Share	-$0.24

Margins

Gross margin is -58.77%, with operating and profit margins of -114.19% and -100.78%.

Gross Margin	-58.77%
Operating Margin	-114.19%
Pretax Margin	-100.78%
Profit Margin	-100.78%
EBITDA Margin	-106.43%
EBIT Margin	-114.19%
FCF Margin	n/a

Dividends & Yields

Innate Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.01%
Shareholder Yield	-1.01%
Earnings Yield	-22.49%
FCF Yield	-11.82%

Analyst Forecast

The average price target for Innate Pharma is $11.50, which is 460.98% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$11.50
Price Target Difference	460.98%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	22.21%
EPS Growth Forecast (5Y)	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Innate Pharma has an Altman Z-Score of -2.42 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.42
Piotroski F-Score	2